183 related articles for article (PubMed ID: 36341543)
21. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer.
Streel S; Salmon A; Dheur A; Bours V; Leroi N; Habran L; Delbecque K; Goffin F; Pleyers C; Kakkos A; Gonne E; Seidel L; Kridelka F; Gennigens C
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902292
[TBL] [Abstract][Full Text] [Related]
24. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
25. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
26. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
27. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract][Full Text] [Related]
28. [Molecular classification and clinicopathological features of endometrial carcinoma].
Li WQ; Shen Y
Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):993-999. PubMed ID: 36207912
[No Abstract] [Full Text] [Related]
29. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
30. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
[TBL] [Abstract][Full Text] [Related]
31. One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
Li Y; Chen R; Yuan M; Wang D; Fu C; Chen R; Lei C; Zhou Q
Int J Cancer; 2022 Dec; 151(11):1969-1977. PubMed ID: 36036365
[TBL] [Abstract][Full Text] [Related]
32. DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens.
Pradhan M; Abeler VM; Davidson B; Kildal W; Nybøen A; Tropé CG; Risberg B; Danielsen HE
Int J Gynecol Pathol; 2010 Nov; 29(6):572-8. PubMed ID: 20881853
[TBL] [Abstract][Full Text] [Related]
33. Concurrent endometrial carcinoma in hysterectomy specimens in patients with histopathological diagnosis of endometrial hyperplasia in curettage specimens.
Dolanbay M; Kutuk MS; Uludag S; Bulut AN; Ozgun MT; Ozcelik B; Serin IS
Ginekol Pol; 2015 Oct; 86(10):753-8. PubMed ID: 26677585
[TBL] [Abstract][Full Text] [Related]
34. Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.
Obeidat BR; Matalka II; Mohtaseb AA; Al-Kaisi NS
Pathol Oncol Res; 2013 Apr; 19(2):229-35. PubMed ID: 23055021
[TBL] [Abstract][Full Text] [Related]
35. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
36. Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2008 Sep; 91(9):1313-7. PubMed ID: 18843857
[TBL] [Abstract][Full Text] [Related]
37. A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers.
Li Y; Feng J; Zhao C; Meng L; Shi S; Liu K; Ma J
Ann Transl Med; 2022 Aug; 10(16):870. PubMed ID: 36111057
[TBL] [Abstract][Full Text] [Related]
38. Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma.
Wang X; Zhang H; Di W; Li W
Am J Obstet Gynecol; 2009 Aug; 201(2):194.e1-194.e10. PubMed ID: 19564019
[TBL] [Abstract][Full Text] [Related]
39. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract][Full Text] [Related]
40. Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel.
Li L; Chen F; Liu J; Zhu W; Lin L; Chen L; Shi Y; Lin A; Chen G
Front Oncol; 2022; 12():935694. PubMed ID: 36003784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
